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study in reconstructive breast surgery
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Abstract
Background: The development and use of core outcome sets (COSs) in trials may improve data synthesis and
reduce outcome reporting bias. The selection of outcomes in COSs is informed by views of key stakeholders, yet
little is known about the role and influence of different stakeholders’ views during COS development. We report an
exploratory case study examining how stakeholder selection and incorporation of stakeholders’ views may influence
the selection of outcomes for a COS in reconstructive breast surgery (RBS). We also make recommendations for
future considerations.
Methods: Key stakeholder groups and subgroups were identified from the literature and expert opinion by the
COS management group. They included health care professionals, subdivided by profession (breast and plastic
surgeons, specialist nurses and psychologists) and patients, subdivided according to type of surgery received,
timing of reconstruction, time since surgery and patient age. All participated in a survey in which they were asked
to prioritise outcomes. Outcomes were prioritised using a 9-point scale from 1 (not important) to 9 (extremely
important). The proportion of (1) all participants, ignoring stakeholder group (single heterogeneous panel analysis),
(2) ‘professional’ and ‘patient’ groups separately (two heterogeneous panels), ignoring prespecified subgroups and
(3) each participant subgroup separately (multiple homogeneous panel analysis) rating each item ‘extremely
important’ was summarised and compared to explore how selection and integration of stakeholder views may
influence outcome prioritisation.
Results: There were many overlaps between items rated as most important by all groups. Specific stakeholders,
however, prioritised specific concerns and a broader range of outcomes were prioritised when the subgroups were
considered separately. For example, two additional outcomes were prioritised when patient and professional
groups were considered separately and eight additional outcomes were identified when the views of the individual
subgroups were explored. In general, patient subgroups preferentially valued additional clinical outcomes, including
unplanned surgery, whereas professional subgroups prioritised additional psychosocial issues including body image.
Conclusion: Stakeholder groups value different outcomes. Selection of groups, therefore, is important. Our
recommendations for robust and transparent stakeholder selection and integration of stakeholder views may aid
future COS developers in the design and conduct of their studies and improve the validity and value of future COS.
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Background
The careful selection of meaningful end points is essen-
tial for research to inform clinical practice and guide
health policy [1, 2]. A number of systematic reviews,
however, have demonstrated a lack of consistency in the
way that outcomes are assessed and reported [3–8]. Het-
erogeneity of outcome reporting limits cross-study com-
parison, precludes data synthesis and introduces the
possibility of reporting bias [9]. One solution to incon-
sistent and inappropriate outcome reporting is to de-
velop and use core outcome sets (COSs), a scientifically
agreed minimum set of outcomes to be measured and
reported in all effectiveness studies of a given condition
[10, 11]. Core outcome sets have been developed in a
number of areas [12–15]. Their development typically
involves the identification of an exhaustive list of out-
comes, then prioritisation of the outcomes by stake-
holders using consensus methods such as Delphi surveys
[10, 16, 17]. Delphi surveys require participants to rate
the importance of different outcomes in sequential ques-
tionnaires (or rounds), with responses to each outcome
summarised and fed back anonymously in subsequent
rounds [16]. This feedback enables participants to change
their initial scores in light of others’ views. Although guid-
ance for this process is emerging [10], the precise method-
ology is yet to be agreed [11, 16]. A Delphi survey may
lead directly to the final COS or may inform one or more
subsequent consensus meetings at which the final core set
is agreed [10].
Stakeholders are critical to COS development since it
is their views which inform the final core set. If import-
ant stakeholders are not included, key outcomes may be
omitted [18] meaning that the COS is of little future
value. Recommendations for Delphi surveys suggest that
involvement of health professionals and patients is es-
sential for developing a COS for pragmatic trials [10,
16]. Yet, within health professional and patient groups
there are likely to be important subgroups whose views
should be considered. For example, health professionals
might include surgeons, physicians, nurses, physiothera-
pists and psychologists, each of whom may have differ-
ent views. There are currently few recommendations as
to how ‘key’ stakeholder groups and subgroups should
be defined and selected [14].
There is also debate as to how stakeholders’ views
should be amalgamated during the Delphi process [18].
One approach is for participants to be considered a het-
erogeneous single panel, ignoring stakeholder type, when
generating and presenting feedback and determining
items to retain for the next stage of the consensus
process. Alternatively, participants can be treated as
multiple homogeneous panels with stakeholders consid-
ered to be distinct groups; feedback from each stake-
holder group is generated and criteria for retaining
items are based on the separate stakeholder groups [18].
Robust and transparent methods for the integration of
views are vital if the value of future COSs is to be
optimised, ensuring that the final COS has credibility in
the relevant clinical field and among the research
community.
Reconstructive breast surgery (RBS) is a complex area
as there are a number of different types of reconstructive
procedures that can be performed [19]. These range in
complexity from expander-implant-based reconstruction
to microvascular free-flap techniques. Each procedure
has specific risks and benefits. For example, implant-
based reconstruction is a simple procedure with a
quick recovery that produces good results but may
require revision over time; whereas free-flap recon-
structions are longer, more complex procedures that
produce excellent long-term cosmetic results, but have
a longer recovery and the risk of donor-site morbidity.
Patients electing to undergo different types of recon-
struction may prioritise and value outcomes differently
[20, 21]. Other factors, including patients’ age, whether
they elect to undergo reconstruction at the time of
their mastectomy or at a later date and the time
elapsed since the original surgery, have also been
shown to impact on which outcomes are valued [20].
Similarly, professional stakeholders in breast recon-
struction include breast and plastic surgeons, clinical
nurse specialists (CNS) and psychologists, and each
subgroup may have different views as to what out-
comes are most important.
Using RBS as a case study, the aim of this paper was
to explore to what extent decisions regarding stake-
holder selection and integration of stakeholder views
within Delphi surveys may influence the content of a
COS and to propose a framework for use in future stud-
ies. The recommendations may also inform consensus
methods other than Delphi methodology.
Methods
This research was integrated into the BRAVO study
which developed a COS for RBS [15]. Full ethical ap-
proval was obtained for the study (REC-11/SW/0305).
The BRAVO study is reported in detail elsewhere
[15], but in brief the study consisted of three phases:
phase 1 – creation of a questionnaire with an exhaust-
ive list of potential outcomes identified from systematic
literature reviews and qualitative work with patients
and health care professionals; phase 2 – two sequential
surveys with 303 key stakeholders (215 patients and 88
health care professionals) using Delphi methods to pri-
oritise outcomes; phase 3 – two consensus meetings,
one with patients and one with professionals to agree
the COS. This paper is informed by the initial round-1
Delphi survey conducted in phase 2.
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Stakeholder selection
Key stakeholders and important stakeholder subgroups
were identified based on the literature [22–26], previous
qualitative work [20, 21, 27–31] and expert opinion by
the BRAVO Steering Group. Broadly, these included
health care professionals and patients. The professional
group was subdivided into breast surgeons, plastic sur-
geons, CNS and psychologists; the patient group was
subdivided based on age, type and timing of reconstruc-
tion and time since surgery.
Professionals were purposively recruited from breast
and plastic surgical units across the UK using the quali-
tative approach of maximum variation sampling [32].
Variation was sought with regard to type of centre
(teaching hospital versus district general hospital), gen-
der and duration of practice to ensure a comprehensive
representation of views. These variables were not con-
sidered to constitute specific professional subgroups in
this study as there is no evidence to suggest that these
factors would influence item prioritisation in a Delphi
process. A priori, the aim was to recruit 30 breast sur-
geons, 30 plastic surgeons, 30 CNS and 10 psychologists.
This ratio was chosen because surgeons and specialist
nurses are involved in the decision-making process for
all patients whereas psychologists have an important role
but do not see every patient prior to surgery.
Patients were purposively sampled from three centres
(Bristol, Liverpool and Glasgow). Qualitative maximum
variation sampling methodology [33] was again used to
ensure that each prespecified patient subgroup was ad-
equately sampled. These groups included women
undergoing each of the four main types of RBS (ex-
pander/implant, latissimus dorsi flap, abdominal flap
reconstruction and therapeutic mammaplasty); those
who had undergone reconstruction at the same time as
their mastectomy (immediate reconstruction) or as a
delayed procedure; women who had had surgery in the
recent past, defined as occurring within 24 months of
questionnaire completion, and those who had had sur-
gery more than 2 years prior to participating in the
study; and young (under 45 years), middle-aged (45–60
years) and older women (over 60 years). The subgroups
were selected based on the findings of earlier qualitative
work [20, 21, 28] which suggested that each factor may
influence outcome prioritisation. This approach was
chosen to ensure that the widest breadth of views was
included in the COS development process. Based on
this sampling strategy, it was anticipated that approxi-
mately 200 patients would be recruited to the study.
Questionnaire survey
Questionnaires asked participants to score the import-
ance of each of 34 outcomes on the 1–9 point scale (1
‘not important, 9 ‘extremely important’) proposed by the
GRADE Group (www.gradeworkinggroup.org) and rec-
ommended by the COMET Initiative [10]. Outcomes
considered short- and long-term complications, symp-
toms following surgery, psychosocial issues, practical is-
sues and cosmesis. Nonresponders were sent a reminder
3 weeks later. Batches of invitations were sent until the
desired sample size was achieved or until the sample
pool had been exhausted.
Data analysis
The number and percentage of participants rating an
item ‘extremely important’ (score of 9) were calculated
for each item; items were then ranked and the ‘top 10’
identified. This was done in three different ways, for: (1)
the whole group, ignoring stakeholder status (single het-
erogeneous panel analysis), (2) broad ‘patient’ and ‘pro-
fessional’ groups, ignoring stakeholder subgroups (two
heterogeneous panels) and (3) prespecified professional
(breast surgeons, plastic surgeons, CNS and psycholo-
gists) and patient (age, type and timing of surgery and
time elapsed since surgery) stakeholder subgroups separ-
ately (multiple homogeneous panels). The top 10 items
for the whole group, each broad stakeholder group and
each stakeholder subgroup were compared to explore
how stakeholder selection and integration of stakeholder
views may influence the contents of a COS. Stata version
14 was used for all analyses [34].
Results
One hundred and fifty-six professionals were invited to
participate of whom 88 (56.4 %) completed and returned
the questionnaire. This included 40 breast surgeons, 21
plastic surgeons, 20 CNS and seven psychologists from
centres across the UK with a range of experience. Re-
sponse rates were 71.4 % (40/56), 46.7 % (21/45), 44.4 %
(20/45) and 63.6 % (7/11) for breast surgeons, plastic
surgeons, CNS and psychologists, respectively. Fewer
plastic surgeons, CNS and psychologists participated
than hoped due to difficulty engaging these stakeholders;
recruitment continued until the sample pool was
exhausted. There was an even mix of men and women
and there was a wide spread of years in post (Table 1).
Four hundred and thirty-four patients from three cen-
tres were invited to take part in the study of whom 242
(55.8 %) consented to participate and 215 (49.5 %) com-
pleted and returned the questionnaire. A good representa-
tion of each of the prespecified subgroups was obtained
with the exception of women undergoing therapeutic
mammaplasty (Table 1). Despite recruiting until the sam-
ple pool was exhausted, this group remained relatively
under-represented with only 11.6 % (n = 25) of respon-
dents undergoing this procedure type.
Table 2 presents all 34 outcomes included in the ques-
tionnaire and indicates the top 10 outcomes prioritised
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as ‘extremely important’ (score of 9) by: (1) the whole
group, ignoring stakeholder status, (2) broad ‘patient’
and ‘professional’ groups ignoring stakeholder subgroups
and (3) professional and patient stakeholder subgroups
separately. Differences in the items prioritised are sum-
marised in Table 3.
The whole group, ignoring stakeholder status
(single heterogeneous panel)
When the participants were considered as a single het-
erogeneous panel ignoring any stakeholder status, the
top 10 outcomes prioritised included three short-term
complications, five psychosocial and two cosmetic out-
comes (Table 2).
Broad ‘professional’ and ‘patient’ groups, ignoring
stakeholder subgroups (two heterogeneous panels)
Professionals
The top 10 outcomes prioritised by the professional
stakeholder group were identical to those observed when
participants were amalgamated as a whole group (see (1)
in the preceding text and Table 2).
Patients
There were nine outcomes prioritised in the patients’
top 10 that were also prioritised by the whole group.
However, two additional clinical outcomes (wound-related
complications and unplanned surgery) were prioritised by
the patient group (11 outcomes were included in the pa-
tients’ top 10 since there were two items rated 9 by the
same percentage of patients). In addition, one outcome
(body image), which was prioritised by the whole group
was not prioritised by patients.
Table 1 Demographics of participants in the BRAVO study
Professional participants Number = 88
(%)
Gender
Female 46 (52.3)
Profession
Consultant breast surgeon 40 (45.5)
Consultant plastic surgeon 21 (23.9)
Clinical nurse specialist 20 (22.7)
Psychologist 7 (8.0)
Time in post
<5 years 18 (20.5)
5–10 years 30 (34.1)
10–20 years 29 (33.0)
>20 years 8 (9.1)
Missing 3 (3.4)
Patient participants (Number = 215)
(%)
Centre
Bristol 77 (35.8)
Liverpool 74 (34.4)
Glasgow 64 (29.8)
Agea
<45 years 21 (9.8)
5–65 years 166 (77.2)
>65 years 28 (13.0)
Median age (range) 54 (29–76)
Time since breast reconstructionb
0–24 months 72 (33.5)
25–48 months 88 (40.9)
>48 months 49 (22.8)
Missing 6 (2.8)
Median (range, months) 33 (4–97)
Timing of surgery
Immediate reconstruction 110 (51.2)
Delayed reconstruction 80 (37.2)
Therapeutic mammoplasty 25 (11.6)
Type of surgery
Implant-based reconstruction 54 (25.1)
Latissimus dorsi flap 59 (27.4)
Abdominal flap 74 (34.4)
Therapeutic mammoplasty 25 (11.6)
Otherc 3 (1.4)
Education
Compulsory only 65 (30.2)
Additional education 139 (64.7)
Missing 11 (5.1)
Table 1 Demographics of participants in the BRAVO study
(Continued)
Marital status
Single 23 (10.7)
Married/living with partner 153 (71.2)
Separated or divorced 28 (13.0)
Widowed 6 (2.8)
Missing 5 (2.3)
Employment status
Full- or part-time employment 130 (60.5)
Homemaker/housewife 17 (7.9)
Retired 45 (20.9)
Not working 16 (7.4)
Missing 7 (3.3)
aAt the time of breast reconstruction; bAt the time of entering the study;
cPatients undergoing bilateral complex surgery who could not be classified
into any one group
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Table 2 Top 10 concerns prioritised by stakeholder groups in the BRAVO study
Items prioritised in ‘top 10’
concerns
All
stakeholders
combined
All
HCPs
Professional subgroup All
patients
Patient subgroups
Type of reconstructive surgery Timing of
reconstruction
Age of women
undergoing BR
(years)
Time since BR
Breast
surgeon
Plastic
surgeon
CNS Psych Implant-based LD
flaps
Abdo
flap
TM IBR DBR <45 45–60 >60 <24 months
post-op
>24 months
post-op
Short-term complications
Systemic complications ✓ ✓
Bleeding-related complications ✓ ✓ ✓ ✓ ✓
Wound-related complications ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Implant-related complications ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Flap-related complications ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Major complications ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Long-term complications
Long-term implant-related
complications
✓ ✓ ✓ ✓ ✓
Long-term flap-related
complications
Donor-site complications ✓
Unplanned surgery for any
reason
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Symptoms following reconstructive breast surgery
Fatigue
Breast symptoms
Arm and shoulder symptoms
Implant-related symptoms
Donor-site symptoms
Psychosocial issues
Self-esteem ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Body image ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Normality ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Emotional well-being ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Sexual well-being ✓ ✓ ✓
Quality of life ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
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Table 2 Top 10 concerns prioritised by stakeholder groups in the BRAVO study (Continued)
Practical issues
Physical well-being
Recovery time
Duration of the procedure
Time to completion of breast
reconstruction
Number of procedures required
Clothing issues
Financial issues
Economic issues
Cosmesis
Patient-reported cosmetic
outcome
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Objective cosmetic outcome ✓ ✓
Cosmetic outcome assessed by
patient’s partner
Women’s cosmetic satisfaction ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Abdo flaps abdominal flap reconstruction, BR breast reconstruction, CNS clinical nurse specialists, DBR delayed breast reconstruction, HCP health care professionals, IBR immediate breast reconstruction, LD latissimus
dorsi flaps, post-op time post-operatively, psych psychologists, RBS reconstructive breast surgery, TM therapeutic mammaplasty
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Professional and patient stakeholder subgroups
(multiple homogeneous panel)
Professional stakeholder subgroups
Differences were seen when the professional subgroups
were considered separately compared to when all profes-
sionals were amalgamated. Four additional outcomes in-
cluding one short-term complication, two long-term
complications and one psychosocial issue were prioritised as
top 10 concerns by at least one professional subgroup when
they were considered separately. One of these items, sexual
well-being, was prioritised by three of the four professional
groups, but did not reach the top 10 when the four groups
were combined in a broad professional stakeholder group.
Of the 34 outcomes, the four subgroups agreed on 21
items not prioritised in their top 10 (primarily symptoms
after surgery and practical issues). Only five (two clinical
outcomes and three psychosocial issues) were common
to the top 10 items for all four professional subgroups
(Table 2).
Patient subgroup analysis
Additional items were prioritised when patients were sub-
divided based on each of the predefined patient subgroups
(type of procedure, timing of procedure, time since sur-
gery and age of patient). Bleeding-related complications,
which was not in the top 10 when considering all patients
together, was prioritised by at least one subgroup within
type of procedure, timing of procedure, time since surgery
and age of patient. Long-term implant complications were
prioritised by one or more subgroups within type of pro-
cedure, timing of procedure and patient age; body image
was prioritised within type, timing and time since proced-
ure; systemic complications within time since surgery and
age of patient; and objective cosmetic outcome within
type of procedure and age of patient (Table 2).
Within each of the patient subgroups there was a de-
gree of disagreement. Within type of procedure, whilst
all four subgroups agreed that seven out of the 34 items
were in the top 10 concerns and that 19 were not, there
was no consensus on the remaining eight outcomes.
Within timing of procedure, both subgroups were in
agreement on 27 items (seven prioritised and 20 not
prioritised by both subgroups); for time since procedure,
there was agreement for 30 items (seven prioritised and
23 not); and for age, all four subgroups agreed on 28
items (9 prioritised and 19 not) (Table 2).
Table 3 Summary of outcomes prioritised by using different approaches to the integration of stakeholders’ views
Single heterogeneous panel analysis
(outcomes prioritised by all participants
combined ignoring stakeholder groups) (n= 10)
Two heterogeneous panel analysis (outcomes
prioritised considering professionals and patients
separately but ignoring prespecified subgroups) (n= 12)
Multiple homogeneous panel analysis
(outcomes prioritised considering professional
and patients subgroups separately) (n= 18)
Short-term complications (n = 3) Short-term complications (n = 4) Short-term complications (n = 6)
Implant-related complications
Flap-related complications
Major complications
Wound-related complications (Pt)
Implant-related complications (Both)
Flap-related complications (Both)
Major complications (Both)
Systemic complications (Pt-SG3, Pt-SG4)
Bleeding-related complications (Pt-SG1, Pt-SG2,
Pt-SG3, Pt-SG4)
Wound-related complications (P-SG) (Pt-SG1,
Pt-SG2, Pt-SG3, Pt-SG4)
Implant-related complications (all)
Flap-related complications (all)
Major complications (all)
Long-term complications (n = 0) Long-term complications (n = 1) Long-term complications (n = 3)
Unplanned surgery for any reason (Pt) Long-term implant-related complications (P-SG)
(Pt-SG1, Pt-SG2, Pt-SG3)
Donor-site complications (Pt-SG3)
Unplanned surgery for any reason (P-SG)
(Pt-SG1, Pt-SG2, Pt-SG3, Pt-SG4)
Psychosocial issues (n = 5) Psychosocial issues (n = 5) Psychosocial issues (n = 6)
Self-esteem
Body image
Normality
Emotional well-being
Quality of life
Self-esteem (Both)
Body image (P)
Normality (Both)
Emotional well-being (Both)
Quality of life (Both)
Self-esteem (all)
Body image (all)
Normality (all)
Emotional well-being (all)
Sexual well-being (P-SG)
Quality of life (all)
Cosmesis (n = 2) Cosmesis (n = 2) Cosmesis (n = 3)
Patient-reported cosmetic outcome
Women’s cosmetic satisfaction
Patient-reported cosmetic outcome (Both)
Women’s cosmetic satisfaction (Both)
Patient-reported cosmetic outcome (all)
Objective cosmetic outcome (Pt-SG1, Pt-SG3)
Women’s cosmetic satisfaction (all)
Items in italics are those identified as the top 10 priorities at each stage of the analysis by a specific stakeholder group or subgroup ; group or subgroup
prioritising the outcome is given in brackets
P professional group, P-SG professional subgroup, Pt patient group, Pt-SG1 patient subgroup 1 (type of reconstructive surgery), Pt-SG2 patient subgroup 2 (timing
of reconstructive surgery), Pt-SG3 patient subgroup 3 (age of women undergoing reconstruction), Pt-SG4 patient subgroup 4 (time since breast reconstruction)
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Recommendations for stakeholder selection and the
integration of stakeholder views in the development of
COSs
This work suggests that decisions regarding stakeholder
selection and integration of stakeholder views within
Delphi surveys may significantly influence the content of
a COS. We therefore propose the following recommen-
dations as a framework for use in future COS develop-
ment studies (Table 4).
We recommend careful selection of relevant stake-
holder groups and subgroups a-priori informed by the
published literature and expert opinion (Table 4). These
decisions should be agreed and documented at the start
of the study and reported to aid transparency. Partici-
pants should then be treated as multiple homogeneous
panels and feedback generated and presented for each
panel separately and criteria for retaining items based on
individual panels. The development of the COS will be
more robust and transparent if all stakeholders’ views
are appropriately considered and valued at every stage,
this should also improve subsequent uptake. If there are
numerous panels, or some much smaller than others,
one approach would be to define consensus with com-
bination criteria. For example, an outcome must be
scored 7–9 by at least 60 % of participants in at least
three out of four stakeholder groups [35]. Further work
is needed to determine the most appropriate way to do
this.
Discussion
This paper has explored the impact of analysing results
from a Delphi survey by broad stakeholder groups
(professionals and patients) and specific stakeholder
subgroups, on the top 10 items prioritised for a COS.
When the participants were considered as two broad
stakeholder groups (two heterogeneous panels), two
additional outcomes were prioritised compared to when
participants were considered as a single heterogeneous
group. Six further items were prioritised when partici-
pants were treated as multiple heterogeneous panels
(professional and patient) (Table 3). Pooling broad stake-
holder groups or all the participant data led to oversim-
plification of views of the study participants, with
potentially important outcomes being lost. Decisions as
to which stakeholders to include in a Delphi process and
how to integrate them (in terms of single or multiple
panels) in the presentation of feedback and consensus
criteria are likely, therefore, to impact on the final COS.
Indeed, donor site complications, an outcome that was
only prioritised by one patient subgroup in the initial
round of the Delphi process was ultimately included in
the final COS for RBS [15].
Breast reconstruction is a particularly complex area,
yet this exploratory work demonstrates the importance
of a comprehensive sampling of stakeholders to include
in a Delphi survey to select a COS. The application of
qualitative techniques, such as maximum variation sam-
pling with or without a sampling matrix, may provide a
robust framework for this, although other methods may
also be appropriate.
Other studies have demonstrated the importance of
stakeholder selection in the development of COSs [9].
For example, when the set for rheumatoid arthritis was
developed by the OMERACT group it did not include
patients’ views [36–38]. Subsequent patient involvement
demonstrated that fatigue was central from their per-
spective. This was added to the COS, highlighting, on a
broad level, the importance of including all relevant
stakeholder views [36]. Other Delphi surveys conducted
as part of COS development have previously considered
Table 4 Recommendations for stakeholder selection and the integration of stakeholder views in the development of core outcome sets
1 Identify all potential stakeholder groups and subgroups from the literature and expert opinion.
Study Steering Group to consider all stakeholders and justify and document choice
2 The final sample size will be informed by the number of subgroups. Each subgroup should include sufficient numbers of individuals to ensure
adequate representation of that group’s views. Further work is required to determine optimal numbers. Decisions regarding target numbers of
individuals for each subgroup to be made, documented and justified by the study Steering Group.
Any anticipated problems with recruitment and possible fall-back positions to be documented
3 Analyse prespecified stakeholder groups and subgroups separately using a multiple homogeneous panel approach. Item prioritisation criteria
should then be applied to each individual stakeholder subgroup to determine which items are to be carried forward to the next round/consensus
meeting and results presented to the Steering Group for consideration
4 Any item which meets the cut-off criteria for inclusion in any prespecified stakeholder subgroup should ideally be carried forward to the next
round/consensus meeting irrespective of whether the item is prioritised by the group as a whole. If there are a large number of subgroups
(for example, >5) or some much smaller than others, higher thresholds may be necessary for an item to be retained if prioritised by a single
subgroup only or consensus may be defined with combination criteria; for example, items are only retained if inclusion criteria are met by 2 or more
subgroups. Decisions regarding these criteria should be discussed and agreed by the Steering Group and the rationale for the decisions recorded
5 Any item for which uncertainty remains should be carried forward to the next Delphi round or discussed at consensus meetings. Any reason(s)
why this should not be done should be discussed by the Steering Group and the justifications recorded
6 If consensus is not achieved following the Delphi process, one or more consensus meetings are advocated. Meetings should be attended by
representatives of each prespecified stakeholder subgroup. Any reason(s) why this should not be done should be discussed by the Steering Group
and the justifications recorded
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participants from professional and patient stakeholder
groups and subgroups [14, 39, 40], but we are not aware
of any that examined how this may influence selection
of outcomes. Recent methodological work suggests that
all participants should receive feedback for each stake-
holder group [18] or stakeholder subgroup [14] separ-
ately to optimise consensus during the process of
selecting COSs. This present study highlights differences
in opinion across all of the stakeholder subgroups; pre-
senting separate feedback for each subgroup enables par-
ticipants to reconsider their scores in light of different
views, hence enabling better consensus to follow. If
stakeholder subgroups or broad groups are pooled, dif-
ferences in opinion will be lost and potential consensus
across stakeholder groups or subgroups reduced.
For the purposes of this methodological study we
chose to rank outcomes based on the percentage of par-
ticipants rating an item ‘extremely important’ (score of
9) and the top 10 outcomes identified. Core outcome set
developers use a variety of consensus criteria within Del-
phi surveys for determining which outcomes should be
included in the COS or taken forward to the next stage
of the consensus process [17]. Commonly, these relate
to a mean or median value for each outcome or a per-
centage of participants scoring an outcome as ‘import-
ant’. The top 10 was selected for this study to make
comparisons across the different panels more straight-
forward; any other approach is likely to have identified
similar differences in the outcomes prioritised.
Whilst this study suggests that all potentially relevant
stakeholder subgroups should be considered as multiple
homogeneous panels in a Delphi survey, it may not be
possible to identify all the characteristics which influence
outcome prioritisation. It may also not be feasible to ad-
equately sample all identified stakeholder subgroups.
Furthermore, different stakeholder characteristics (e.g.
age and reconstruction type) may interact to influence
which outcomes are valued. Such interactions may be
difficult to disentangle in a Delphi process and preliminary
qualitative work with stakeholders may be required to
allow meaningful subgroups to be selected. In addition, it
may be possible to conceive an almost infinite number of
subgroups for a given condition. This would almost inevit-
ably lead to under-representation of any single group and,
depending on the criteria used to retain items, may lead
to the retention of an unwieldy number of outcomes.
Large numbers of subgroups may also complicate the
provision of feedback in the Delphi process. Type of feed-
back has been shown to influence the prioritisation of out-
comes in COS development [18]. How feedback is
provided in the context of multiple stakeholder subgroups
would, therefore, require careful consideration and further
work is needed to determine how this process may be
optimised. There is a need, therefore, to identify a
priori the key professional and patient characteristics
to consider as separate panels during the Delphi, ideally
based on previous evidence. Breadth of experience can
then be ensured with maximum variation sampling within
each predefined subgroup.
It may also be argued that since the aim of the consen-
sus methods is to determine a minimum ‘core’ outcome
set, variation in outcome prioritisation by stakeholder
subgroups at early stages in the process may be irrele-
vant since differences may disappear as the consensus
process moves forward. However, if items are dropped
early on because they are not deemed important by par-
ticipants as a whole, or by all professionals or all pa-
tients; or if feedback is not presented for each subgroup
separately, consensus across all stakeholders cannot be
fully achieved.
Finally, this study may have implications beyond the
Delphi process. One or more consensus meetings are an
important step in agreeing and ratifying the final COS if
uncertainty remains following the Delphi. Extrapolating
the findings of this study, adequate representation from
each identified stakeholder subgroup at these meeting
would be vital to allow meaningful consensus to emerge.
This may not be feasible if multiple stakeholder sub-
groups are involved, but should be advocated as best
practice in future COS development studies when con-
sensus meetings are considered necessary.
Conclusions
Core outcome sets can improve the quality and consistency
of research and, hence, its value to patients, professionals
and policy-makers [10]. Careful and appropriate stake-
holder selection and integration of stakeholder views,
however, are necessary to ensure that the resultant COS is
valid and accepted. Further work is required to produce
definitive guidance on this important issue, but the formal,
robust and transparent recommendations presented here
may aid future COS developers in the design and conduct
of their studies and may be the first step to improving the
validity and value of COSs. Widespread adoption of these
recommendations may, therefore, promote the uptake and
use of future COSs in practice.
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